Atara reports FY2022 net loss $228.3M, CFO transition, Ebvallo EU launch

Atara Biotherapeutics, Inc.

2022-FY EPS reported -$2.24 revenue$63,573,000

Cash and investments $242.8M as of Dec 31, 2022; runway extended into Q2 2024.
Net loss $228.3M ($2.24/share) for FY2022 vs $340.1M ($3.63/share) in FY2021.
CFO Utpal Koppikar resigns effective March 31, 2023; Eric Hyllengren appointed CFO effective April 1, 2023.
Ebvallo EU launch led by Pierre Fabre to begin Q1 2023; FDA discussions ongoing for tab-cel BLA.
ATA188 Phase 2 EMBOLD primary data readout on track for October 2023.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Utpal Koppikar

Executive Vice President, Chief Financial Officer

ATRA · Atara Biotherapeutics, Inc.

Effective: 2023-03-31
Successor: Eric Hyllengren
Filed: February 8, 2023, 6:59 PM ET

Utpal Koppikar, the Company’s Executive Vice President, Chief Financial Officer, notified the Company of his intention to resign from the Company, effective March 31, 2023, to pursue an external opportunity.

Appointed

Eric Hyllengren

Senior Vice President, Chief Financial Officer

ATRA · Atara Biotherapeutics, Inc.

Effective: 2023-04-01
Filed: February 8, 2023, 6:59 PM ET

the Company appointed Eric Hyllengren, the Company’s Senior Vice President, Finance, to serve as the Company’s Senior Vice President, Chief Financial Officer, effective as of April 1, 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.75

Atara Biotherapeutics, Inc. reported the fourth quarter and year ended December 31, 2022 results: net income $74.6 million, or $0.72 per share, and $228.3 million, or $2.24 per share, for the fourth quarter and fiscal year 2022, EPS $0.72 per share, and ... $2.24 per share.

Period: the fourth quarter and year ended December 31, 2022
Net income: $74.6 million, or $0.72 per share, and $228.3 million, or $2.24 per share, for the fourth quarter and fiscal year 2022
EPS: $0.72 per share, and ... $2.24 per share
Result: reported results

Exact text from the filing

On February 8, 2023, Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”) announced certain financial results for the fourth quarter and year ended December 31, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Utpal Koppikar resigned as Executive Vice President, Chief Financial Officer at Atara Biotherapeutics, Inc..

Action: resigned
Role: Executive Vice President, Chief Financial Officer

Exact text from the filing

Utpal Koppikar, the Company’s Executive Vice President, Chief Financial Officer, notified the Company of his intention to resign from the Company, effective March 31, 2023, to pursue an external opportunity.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Eric Hyllengren was appointed as Senior Vice President, Chief Financial Officer at Atara Biotherapeutics, Inc..

Action: appointed
Role: Senior Vice President, Chief Financial Officer

Exact text from the filing

the Company appointed Eric Hyllengren, the Company’s Senior Vice President, Finance, to serve as the Company’s Senior Vice President, Chief Financial Officer, effective as of April 1, 2023.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Atara Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-002132

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.